Heart Health: Orticumab for Inflammation After Heart Attack

We are studying whether orticumab can reduce inflammation in people who have had a heart attack and show elevated coronary inflammation. The trial will also evaluate the safety of this treatment.

6-12 months 6-10 visits Efficacy phase (II)Investigational Medicines InjectionCardiologyInternal Medicine

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Epcoritamab

Epcoritamab is a lab-made antibody that helps the immune system target and kill cancerous B cells in certain types of non-Hodgkin lymphoma.

What experimental substances are being tested?

Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.

Orticumab

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...

Fakultni Nemocnice U Sv Anny V Brne

I. interní kardioangiologická klinika

Brno, Czechia

Fakultni Nemocnice Plzen

II. interní klinika

Pilsen, Czechia

Institute For Clinical And Experimental Medicine

preventivní kardiologie

Prague, Czechia

Sponsor: Abcentra LLC

Last updated: Nov 27, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.